Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Traumatic Brain Injury-Pipeline Review, H1 2015

Traumatic Brain Injury-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Traumatic Brain Injury-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Traumatic Brain Injury-Pipeline Review, H1 2015', provides an overview of the Traumatic Brain Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Traumatic Brain Injury Overview 10

Therapeutics Development 11

Pipeline Products for Traumatic Brain Injury-Overview 11

Pipeline Products for Traumatic Brain Injury-Comparative Analysis 12

Traumatic Brain Injury-Therapeutics under Development by Companies 13

Traumatic Brain Injury-Therapeutics under Investigation by Universities/Institutes 18

Traumatic Brain Injury-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Traumatic Brain Injury-Products under Development by Companies 23

Traumatic Brain Injury-Products under Investigation by Universities/Institutes 28

Traumatic Brain Injury-Companies Involved in Therapeutics Development 29

Adamas Pharmaceuticals, Inc. 29

ALSP, Inc. 30

Amarantus Bioscience Holdings, Inc. 31

Athersys, Inc. 32

BHR Pharma, LLC 33

Cognosci, Inc. 34

Concert Pharmaceuticals, Inc. 35

Euroscreen S.A. 36

Grupo Ferrer Internacional, S.A. 37

International Stem Cell Corporation 38

Io Therapeutics, Inc. 39

Ischemix 40

Karyopharm Therapeutics, Inc. 41

Kyorin Pharmaceutical Co., Ltd. 42

Levolta Pharmaceuticals, Inc. 43

Lixte Biotechnology Holdings, Inc. 44

Lpath, Inc. 45

MandalMed, Inc. 46

Mapreg S.A.S. 47

Mnemosyne Pharmaceuticals, Inc. 48

NeoStem, Inc. 49

Neuralstem, Inc. 50

Neuren Pharmaceuticals Limited 51

NeuroHealing Pharmaceuticals Inc. 52

NeuroNascent, Inc. 53

Neuronax SAS 54

NeuroVive Pharmaceutical AB 55

Omeros Corporation 56

PharmatrophiX, Inc. 57

Phylogica Limited 58

Prevacus, Inc. 59

PsychoGenics, Inc. 60

QR Pharma, Inc. 61

RAPID Pharmaceuticals AG 62

RegeneRx Biopharmaceuticals, Inc. 63

Remedy Pharmaceuticals, Inc. 64

Sage Therapeutics 65

SanBio, Inc. 66

STATegics, Inc. 67

SynZyme Technologies, LLC 68

Tetra Discovery Partners LLC 69

vasopharm GmbH 70

VG Life Sciences, Inc. 71

Traumatic Brain Injury-Therapeutics Assessment 72

Assessment by Monotherapy Products 72

Assessment by Combination Products 73

Assessment by Target 74

Assessment by Mechanism of Action 77

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

2-DG-Drug Profile 84

ALP-496-Drug Profile 86

amantadine hydrochloride ER-Drug Profile 88

AMR-001-Drug Profile 90

AMRS-001-Drug Profile 92

apomorphine hydrochloride-Drug Profile 94

AVL-8168-Drug Profile 96

BHR-310-Drug Profile 97

C-10068-Drug Profile 98

Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury-Drug Profile 99

CHEC-7-Drug Profile 100

CHEC-9-Drug Profile 101

CMX-2043-Drug Profile 103

CNB-001-Drug Profile 105

COG-1410-Drug Profile 107

cyclosporine-Drug Profile 109

dexamethasone acetate + melatonin-Drug Profile 112

EPO-Variant-Drug Profile 113

ESN-502-Drug Profile 114

felbamate-Drug Profile 115

FIB-117-Drug Profile 116

glyburide-Drug Profile 117

HBN-1-Drug Profile 119

HBN-2-Drug Profile 120

ibudilast-Drug Profile 121

ICCN-100-Drug Profile 123

IRX-4204-Drug Profile 124

KPT-350-Drug Profile 126

LB-201-Drug Profile 127

LB-205-Drug Profile 128

LM11A-31-Drug Profile 129

Lpathomab-Drug Profile 130

MAP-4343-Drug Profile 131

MultiStem-Drug Profile 132

ND-478-Drug Profile 135

NNI-370-Drug Profile 136

NNZ-2591-Drug Profile 137

NSI-189-Drug Profile 139

NSI-566-Drug Profile 140

NVP-019-Drug Profile 142

NVX-428-Drug Profile 143

NX-210-Drug Profile 144

Peptides for Central Nervous System and Musculoskeletal Disorders-Drug Profile 145

PGI-02776-Drug Profile 146

Posiphen-Drug Profile 148

progesterone-Drug Profile 150

PRV-002-Drug Profile 151

PYC-35-Drug Profile 152

PYC-36-Drug Profile 153

PYC-38-Drug Profile 154

PYC-98-Drug Profile 155

R-503-Drug Profile 156

RAP-701-Drug Profile 158

RGN-352-Drug Profile 159

SAGE-547-Drug Profile 161

SB-623-Drug Profile 163

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury-Drug Profile 164

Small Molecule to Antagonize GPR17 for Central Nervous System Disorders-Drug Profile 165

Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder-Drug Profile 166

Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer's Disease-Drug Profile 167

Small Molecule to Inhibit PDE4 for Traumatic Brain Injury-Drug Profile 168

Small Molecules for Stroke and Traumatic Brain Injury-Drug Profile 169

Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury-Drug Profile 170

Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System-Drug Profile 171

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 172

Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases-Drug Profile 173

Stem Cell Therapy for Parkinson's Disease, Traumatic Brain Injury and Stroke-Drug Profile 174

Stem Cell Therapy for Traumatic Spinal Cord Injury and Brain Injury-Drug Profile 176

STSE-15-Drug Profile 177

TBI-121-Drug Profile 178

TBI-122-Drug Profile 179

TBI-123-Drug Profile 180

trofinetide-Drug Profile 181

UH-0113-Drug Profile 183

UH-0213-Drug Profile 184

VAS-203-Drug Profile 185

VG-1177-Drug Profile 187

VitalHeme-Drug Profile 189

VOLT-02-Drug Profile 191

Traumatic Brain Injury-Recent Pipeline Updates 192

Traumatic Brain Injury-Dormant Projects 245

Traumatic Brain Injury-Discontinued Products 249

Traumatic Brain Injury-Product Development Milestones 250

Featured News & Press Releases 250

Appendix 258

Methodology 258

Coverage 258

Secondary Research 258

Primary Research 258

Expert Panel Validation 258

Contact Us 258

Disclaimer 259

List of Tables

Number of Products under Development for Traumatic Brain Injury, H1 2015 17

Number of Products under Development for Traumatic Brain Injury-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Late Stage Development, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Development, H1 2015 27

Comparative Analysis by Unknown Stage Development, H1 2015 28

Products under Development by Companies, H1 2015 29

Products under Development by Companies, H1 2015 (Contd..1) 30

Products under Development by Companies, H1 2015 (Contd..2) 31

Products under Development by Companies, H1 2015 (Contd..3) 32

Products under Development by Companies, H1 2015 (Contd..4) 33

Products under Investigation by Universities/Institutes, H1 2015 34

Traumatic Brain Injury-Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 35

Traumatic Brain Injury-Pipeline by ALSP, Inc., H1 2015 36

Traumatic Brain Injury-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 37

Traumatic Brain Injury-Pipeline by Athersys, Inc., H1 2015 38

Traumatic Brain Injury-Pipeline by BHR Pharma, LLC, H1 2015 39

Traumatic Brain Injury-Pipeline by Cognosci, Inc., H1 2015 40

Traumatic Brain Injury-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 41

Traumatic Brain Injury-Pipeline by Euroscreen S.A., H1 2015 42

Traumatic Brain Injury-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 43

Traumatic Brain Injury-Pipeline by International Stem Cell Corporation, H1 2015 44

Traumatic Brain Injury-Pipeline by Io Therapeutics, Inc., H1 2015 45

Traumatic Brain Injury-Pipeline by Ischemix, H1 2015 46

Traumatic Brain Injury-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 47

Traumatic Brain Injury-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 48

Traumatic Brain Injury-Pipeline by Levolta Pharmaceuticals, Inc., H1 2015 49

Traumatic Brain Injury-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 50

Traumatic Brain Injury-Pipeline by Lpath, Inc., H1 2015 51

Traumatic Brain Injury-Pipeline by MandalMed, Inc., H1 2015 52

Traumatic Brain Injury-Pipeline by Mapreg S.A.S., H1 2015 53

Traumatic Brain Injury-Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 54

Traumatic Brain Injury-Pipeline by NeoStem, Inc., H1 2015 55

Traumatic Brain Injury-Pipeline by Neuralstem, Inc., H1 2015 56

Traumatic Brain Injury-Pipeline by Neuren Pharmaceuticals Limited, H1 2015 57

Traumatic Brain Injury-Pipeline by NeuroHealing Pharmaceuticals Inc., H1 2015 58

Traumatic Brain Injury-Pipeline by NeuroNascent, Inc., H1 2015 59

Traumatic Brain Injury-Pipeline by Neuronax SAS, H1 2015 60

Traumatic Brain Injury-Pipeline by NeuroVive Pharmaceutical AB, H1 2015 61

Traumatic Brain Injury-Pipeline by Omeros Corporation, H1 2015 62

Traumatic Brain Injury-Pipeline by PharmatrophiX, Inc., H1 2015 63

Traumatic Brain Injury-Pipeline by Phylogica Limited, H1 2015 64

Traumatic Brain Injury-Pipeline by Prevacus, Inc., H1 2015 65

Traumatic Brain Injury-Pipeline by PsychoGenics, Inc., H1 2015 66

Traumatic Brain Injury-Pipeline by QR Pharma, Inc., H1 2015 67

Traumatic Brain Injury-Pipeline by RAPID Pharmaceuticals AG, H1 2015 68

Traumatic Brain Injury-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 69

Traumatic Brain Injury-Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 70

Traumatic Brain Injury-Pipeline by Sage Therapeutics, H1 2015 71

Traumatic Brain Injury-Pipeline by SanBio, Inc., H1 2015 72

Traumatic Brain Injury-Pipeline by STATegics, Inc., H1 2015 73

Traumatic Brain Injury-Pipeline by SynZyme Technologies, LLC, H1 2015 74

Traumatic Brain Injury-Pipeline by Tetra Discovery Partners LLC, H1 2015 75

Traumatic Brain Injury-Pipeline by vasopharm GmbH, H1 2015 76

Traumatic Brain Injury-Pipeline by VG Life Sciences, Inc., H1 2015 77

Assessment by Monotherapy Products, H1 2015 78

Assessment by Combination Products, H1 2015 79

Number of Products by Stage and Target, H1 2015 81

Number of Products by Stage and Mechanism of Action, H1 2015 84

Number of Products by Stage and Route of Administration, H1 2015 87

Number of Products by Stage and Molecule Type, H1 2015 89

Traumatic Brain Injury Therapeutics-Recent Pipeline Updates, H1 2015 198

Traumatic Brain Injury-Dormant Projects, H1 2015 251

Traumatic Brain Injury-Dormant Projects (Contd..1), H1 2015 252

Traumatic Brain Injury-Dormant Projects (Contd..2), H1 2015 253

Traumatic Brain Injury-Dormant Projects (Contd..3), H1 2015 254

Traumatic Brain Injury-Discontinued Products, H1 2015 255

List of Figures

Number of Products under Development for Traumatic Brain Injury, H1 2015 17

Number of Products under Development for Traumatic Brain Injury-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Products, H1 2015 27

Assessment by Monotherapy Products, H1 2015 78

Number of Products by Top 10 Targets, H1 2015 80

Number of Products by Stage and Top 10 Targets, H1 2015 80

Number of Products by Top 10 Mechanism of Actions, H1 2015 83

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 83

Number of Products by Top 10 Routes of Administration, H1 2015 86

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 87

Number of Products by Top 10 Molecule Types, H1 2015 88

Number of Products by Stage and Top 10 Molecule Types, H1 2015 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adamas Pharmaceuticals, Inc.

ALSP, Inc.

Amarantus Bioscience Holdings, Inc.

Athersys, Inc.

BHR Pharma, LLC

Cognosci, Inc.

Concert Pharmaceuticals, Inc.

Euroscreen S.A.

Grupo Ferrer Internacional, S.A.

International Stem Cell Corporation

Io Therapeutics, Inc.

Ischemix

Karyopharm Therapeutics, Inc.

Kyorin Pharmaceutical Co., Ltd.

Levolta Pharmaceuticals, Inc.

Lixte Biotechnology Holdings, Inc.

Lpath, Inc.

MandalMed, Inc.

Mapreg S.A.S.

Mnemosyne Pharmaceuticals, Inc.

NeoStem, Inc.

Neuralstem, Inc.

Neuren Pharmaceuticals Limited

NeuroHealing Pharmaceuticals Inc.

NeuroNascent, Inc.

Neuronax SAS

NeuroVive Pharmaceutical AB

Omeros Corporation

PharmatrophiX, Inc.

Phylogica Limited

Prevacus, Inc.

PsychoGenics, Inc.

QR Pharma, Inc.

RAPID Pharmaceuticals AG

RegeneRx Biopharmaceuticals, Inc.

Remedy Pharmaceuticals, Inc.

Sage Therapeutics

SanBio, Inc.

STATegics, Inc.

SynZyme Technologies, LLC

Tetra Discovery Partners LLC

vasopharm GmbH

VG Life Sciences, Inc.

Traumatic Brain Injury Therapeutic Products under Development, Key Players in Traumatic Brain Injury Therapeutics, Traumatic Brain Injury Pipeline Overview, Traumatic Brain Injury Pipeline, Traumatic Brain Injury Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com